JP7610515B2 - ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体 - Google Patents

ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体 Download PDF

Info

Publication number
JP7610515B2
JP7610515B2 JP2021543565A JP2021543565A JP7610515B2 JP 7610515 B2 JP7610515 B2 JP 7610515B2 JP 2021543565 A JP2021543565 A JP 2021543565A JP 2021543565 A JP2021543565 A JP 2021543565A JP 7610515 B2 JP7610515 B2 JP 7610515B2
Authority
JP
Japan
Prior art keywords
antibody
seq
nt4x
antibodies
humanized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021543565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513331A5 (https=
JP2022513331A (ja
Inventor
トーマス バイエル
プリーティ バクラニア
サラ デイビス
アレックス ブラウン
チド ムパムハンガ
デビッド マシューズ
マーク カー
ガレス ホール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LifeArc
Original Assignee
LifeArc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LifeArc filed Critical LifeArc
Publication of JP2022513331A publication Critical patent/JP2022513331A/ja
Publication of JP2022513331A5 publication Critical patent/JP2022513331A5/ja
Application granted granted Critical
Publication of JP7610515B2 publication Critical patent/JP7610515B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2021543565A 2018-10-04 2019-10-02 ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体 Active JP7610515B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1816210.7 2018-10-04
GB201816210 2018-10-04
PCT/EP2019/076772 WO2020070225A1 (en) 2018-10-04 2019-10-02 Humanised anti-n-truncated amyloid beta monoclonal antibody

Publications (3)

Publication Number Publication Date
JP2022513331A JP2022513331A (ja) 2022-02-07
JP2022513331A5 JP2022513331A5 (https=) 2022-10-06
JP7610515B2 true JP7610515B2 (ja) 2025-01-08

Family

ID=68136417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543565A Active JP7610515B2 (ja) 2018-10-04 2019-10-02 ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体

Country Status (13)

Country Link
US (1) US12297261B2 (https=)
EP (1) EP3861023A1 (https=)
JP (1) JP7610515B2 (https=)
KR (1) KR102862077B1 (https=)
CN (1) CN113056480B (https=)
AU (1) AU2019354714A1 (https=)
BR (1) BR112021006153A2 (https=)
CA (1) CA3114669A1 (https=)
EA (1) EA202190954A1 (https=)
IL (1) IL281979B2 (https=)
MX (1) MX2021003867A (https=)
SG (1) SG11202102765RA (https=)
WO (1) WO2020070225A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4118111A1 (en) 2020-03-10 2023-01-18 LifeArc Cyclic peptides
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US474900A (en) 1892-05-17 William byrnes
US4704362A (en) 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
EP0832981A1 (en) 1987-02-17 1998-04-01 Pharming B.V. DNA sequences to target proteins to the mammary gland for efficient secretion
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
WO2008081008A1 (en) * 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
WO2011151076A2 (en) * 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
WO2015173133A1 (en) 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CA2992386A1 (en) * 2015-07-16 2017-01-19 Probiodrug Ag Humanized antibodies
CN111518206B (zh) * 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
EP4118111A1 (en) * 2020-03-10 2023-01-18 LifeArc Cyclic peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013167681A1 (en) 2012-05-10 2013-11-14 Georg-August-Universität Göttingen CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST Αβ OLIGOMERS

Also Published As

Publication number Publication date
CA3114669A1 (en) 2020-04-09
BR112021006153A2 (pt) 2021-06-29
MX2021003867A (es) 2021-09-08
JP2022513331A (ja) 2022-02-07
EA202190954A1 (ru) 2021-06-29
US20210347867A1 (en) 2021-11-11
EP3861023A1 (en) 2021-08-11
CN113056480A (zh) 2021-06-29
AU2019354714A1 (en) 2021-04-29
SG11202102765RA (en) 2021-04-29
KR102862077B1 (ko) 2025-09-18
IL281979B2 (en) 2025-09-01
KR20210080400A (ko) 2021-06-30
US12297261B2 (en) 2025-05-13
IL281979B1 (en) 2025-05-01
IL281979A (en) 2021-05-31
CN113056480B (zh) 2025-06-13
US20230203140A9 (en) 2023-06-29
WO2020070225A1 (en) 2020-04-09

Similar Documents

Publication Publication Date Title
US20240368263A1 (en) Optimized anti-tl1a antibodies
JP7610515B2 (ja) ヒト化抗Ｎ短縮型アミロイドβモノクローナル抗体
TWI673287B (zh) 抗b7-h3抗體、其抗原結合片段及其醫藥用途
AU2010270241B2 (en) Humanised antibodies to Toll-like Receptor 2 and uses thereof
JP6097690B2 (ja) 抗ｃｘｃｌ１３抗体およびそれを用いる方法
WO2020020281A1 (zh) 抗tigit抗体及其用途
WO2018095428A1 (zh) Cd47抗体、其抗原结合片段及其医药用途
EP3632932A1 (en) Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof
JP2014531210A (ja) ＴＬ１ａに対する抗体およびその使用
JP2025041747A (ja) ヒト化抗ｉｌ１７ｂｒ抗体
TW202144433A (zh) 抗體或其抗原結合片段、其製備方法及醫藥用途
CN114502583A (zh) 补体c2结合蛋白及其用途
WO2025228316A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
WO2026012421A1 (zh) 抗N3pGlu淀粉样蛋白β抗体及其用途
CN120225553A (zh) 抗β-连环蛋白抗体
NZ622092B2 (en) Antibodies against tl1a and uses thereof
NZ622092A (en) Antibodies against tl1a and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220928

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220928

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230904

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240229

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240528

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240820

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241128

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241220

R150 Certificate of patent or registration of utility model

Ref document number: 7610515

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150